Estrella Immunopharma Inc (ESLA) Stock AnalysisESLAEstrella Immunopharma Inc

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Estrella Immunopharma Inc (ESLA) is a good buy right now due to its recent price surge of 129.07% over the last five days, indicating strong momentum. The RSI is at 86.195, suggesting the stock is overbought but also reflects high investor interest. The company has activated a new clinical trial site, which could enhance its growth potential in the oncology sector. However, the main risk is its significant net losses, with a net income of -5,544,878 USD in Q2 2025, indicating ongoing financial challenges.